TWC
SPRY icon

TD Waterhouse Canada’s ARS Pharmaceuticals SPRY Stock Holding History

TD Waterhouse Canada’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1K Hold
2,160
– – ﹤0.01% 1687
2026
Q1 		$17.4K Hold
2,160
– – ﹤0.01% 1624
2025
Q4 		$25.2K Hold
2,160
– – ﹤0.01% 1346
2025
Q3 		$21.8K Hold
2,160
– – ﹤0.01% 1367
2025
Q2 		$34.6K Hold
2,160
– – ﹤0.01% 1196
2025
Q1 		$27K Hold
2,160
– – ﹤0.01% 1209
2024
Q4 		$22.8K Buy
+2,160
New +$30.3K ﹤0.01% 1257

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

TD Waterhouse Canada's SPRY Position: Q2 2026 in Review

TD Waterhouse Canada held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 2,160 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1687.

TD Waterhouse Canada first reported a position in SPRY in Q4 2024 and has held it in 7 quarters since. The position peaked at $34.6K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • TD Waterhouse Canada held 2,160 shares of ARS Pharmaceuticals worth $17.1K as of Q2 2026.
  • TD Waterhouse Canada left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1687 holding.
  • TD Waterhouse Canada first reported a position in ARS Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • TD Waterhouse Canada's ARS Pharmaceuticals position peaked at $34.6K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.